Virtual hepatic venous pressure gradient (vHVPG), a novel noninvasive approach to assess portal hypertension, is shown to correlate well with the gold-standard invasive method in a recent Chinese study.
New endoscopic technologies have improved outcomes for patients with upper gastrointestinal bleeding (UGIB), according to Professor James Lau from the Chinese University of Hong Kong, who reviewed current treatment practices and latest advances at the Asian Pacific Digestive Week (APDW) 2017 held recently in Hong Kong.
Sodium phosphate (NaP) tablets for bowel preparation prior to colonoscopy are safe, better tolerated by patients, and provide equivalent and possibly superior colon cleansing compared with standard polyethylene glycol (PEG) solution, a Korean study has found.
Genotypic resistance-guided therapy is no better than traditional empiric therapy for treating patients with refractory Helibacter pylori infection. Researchers found no significant difference in eradication rate between the two strategies when used in the third-line setting.
While bleeding from the small intestine is relatively uncommon, it often presents a diagnostic challenge. Speaking at the Asian Pacific Digestive Week (APDW) 2017 held recently in Hong Kong, Dr Simon Lo from the Cedars Sinai Medical Center in Los Angeles, California, US, reviewed current guidelines and practices with a special focus on common pitfalls.
An index of three liver-specific microRNAs (the MiR-B Index) could serve as a biomarker of spontaneous or treatment-induced transition from active to inactive chronic hepatitis B virus (HBV) infection, facilitating disease monitoring and testing of new antivirals, according to Dr Mauricia Brunetto from the University of Pisa, Italy, who spoke recently at the Asian Pacific Digestive Week (APDW) 2017 in Hong Kong.
Regardless of birth weight, being obese at preschool age is associated with a greater risk of elevated blood pressure during early childhood, a recent China study has found. A longer duration of breastfeeding appears to help mitigate such a risk.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.